Literature DB >> 17907292

Clinical significance of activity of ALT enzyme in patients with hepatitis C virus.

Onder Akkaya1, Murat Kiyici, Yusuf Yilmaz, Engin Ulukaya, Omer Yerci.   

Abstract

AIM: To investigate serum alanine aminotransferase (ALT) levels in relation to the clinical, biochemical, ultrasonographic and histological characteristics of patients with hepatitis C virus.
METHODS: Duration of disease, HCV-RNA, liver steatosis, and the hepatitis activity index (HAI) were correlated with serum ALT in 36 patients with HCV. ALT values were also investigated in 16 control subjects without any liver diseases.
RESULTS: In bivariate analyses, ALT levels correlated with duration of HCV infection (P < 0.01), HCV-RNA (P < 0.05), and the HAI (P < 0.01). Among the components of the HAI, ALT concentrations were significantly associated with periportal bridging/necrosis (P < 0.01) and fibrosis (P < 0.05). In multivariate analysis, periportal bridging/necrosis (beta = 0.508; P < 0.01), duration of HCV infection (beta = 0.413; P < 0.01), and HCV-RNA (beta = 0.253; P < 0.05) were independently associated with ALT activity. The normal ALT activity for men and women was < 23 IU/L and < 22 IU/L, respectively.
CONCLUSION: In patients with HCV, alterations in the liver tissue as reflected by ALT elevation are mainly associated with periportal bridging/necrosis, viral load and duration of disease. A cut-off value < 23 IU/L distinguished with high diagnostic accuracy healthy controls from patients with HCV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907292      PMCID: PMC4171283          DOI: 10.3748/wjg.v13.i41.5481

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

Authors:  A Piton; T Poynard; F Imbert-Bismut; L Khalil; J Delattre; E Pelissier; N Sansonetti; P Opolon
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

2.  Study of serum alanine-aminotransferase levels in blood donors in Spain.

Authors:  M Lozano; J Cid; J L Bedini; R Mazzara; N Gimenez; E Mas; A Ballesta; A Ordinas
Journal:  Haematologica       Date:  1998-03       Impact factor: 9.941

Review 3.  Management issues in chronic viral hepatitis: hepatitis C.

Authors:  William Sievert
Journal:  J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 4.029

4.  Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors.

Authors:  J F Tsai; J E Jeng; M S Ho; C S Wang; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Liver       Date:  1997-02

Review 5.  Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?

Authors:  C Puoti; R Castellacci; F Montagnese
Journal:  Dig Liver Dis       Date:  2000-10       Impact factor: 4.088

6.  Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C.

Authors:  S E McCormick; Z D Goodman; C L Maydonovitch; M H Sjogren
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

Review 7.  Hepatitis C virus: virology and experimental systems.

Authors:  Chen Liu
Journal:  Clin Liver Dis       Date:  2006-11       Impact factor: 6.126

8.  Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors.

Authors:  Mehdi Mohamadnejad; Akram Pourshams; Reza Malekzadeh; Ashraf Mohamadkhani; Afsaneh Rajabiani; Ali Ali Asgari; Seyed Meysam Alimohamadi; Hadi Razjooyan; Mansooreh Mamar-Abadi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 9.  The natural history of hepatitis C virus infection.

Authors:  Mohammed N Al-Quaiz; Tariq A Madani; Mohamed A Karawi
Journal:  Saudi Med J       Date:  2003-07       Impact factor: 1.484

Review 10.  Hepatitis C virus: virology, diagnosis and management of antiviral therapy.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

View more
  9 in total

1.  Routine blood tests to predict liver fibrosis in chronic hepatitis C.

Authors:  Yung-Yu Hsieh; Shui-Yi Tung; Kamfai Lee; Cheng-Shyong Wu; Kuo-Liang Wei; Chien-Heng Shen; Te-Sheng Chang; Yi-Hsiung Lin
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Redefining the Normal Values of Serum Aminotransferases in Healthy Indian Males.

Authors:  Shaneez Najmy; Ajay Duseja; Arnab Pal; Suchet Sachdev; Rati R Sharma; Neelam Marwah; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2018-06-21

3.  Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study.

Authors:  Ali Asghar Pouri; Morteza Ghojazadeh; Behrouz Pourasghari; Babak Baiaz; Fatemeh Soghra Hamzavi; Mohammad Hossein Somi
Journal:  Caspian J Intern Med       Date:  2019

4.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

Review 5.  A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

Authors:  Waqar Ahmad; Bushra Ijaz; Sana Gull; Sultan Asad; Saba Khaliq; Shah Jahan; Muhammad T Sarwar; Humera Kausar; Aleena Sumrin; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

6.  A novel system for predicting liver histopathology in patients with chronic hepatitis B.

Authors:  An-Na Pan; Wang-Wang Xu; Yun-Lin Luo; Huan-Huan Yu; Yi-Bing Hu; Qing-Feng Sun; Ji-Guang Ding; Yang-He Wu
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Variants in two gene members of the TNF ligand superfamily and hepatitis C virus chronic disease.

Authors:  Shaghayegh Baradaran Ghavami; Seyed Reza Mohebbi; Khatoon Karimi; Pedram Azimzadeh; Afsaneh Sharifian; Helia Mojahed Yazdi; Behzad Hatami
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

8.  Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.

Authors:  Yuri Komaki; Yoshinori Ozono; Kenichi Nakamura; Hisayoshi Iwakiri; Satoru Hasuike; Mitsue Sueta; Tadashi Miike; Shojiro Yamamoto; Hirofumi Uto; Kazunori Kusumoto; Toshimasa Ochiai; Junya Kato; Naoto Komada; Kazuo Kuroki; Toshiharu Eto; Masafumi Shigehira; Shuichi Hirono; Kenji Nagata; Hiroshi Kawakami
Journal:  BMC Gastroenterol       Date:  2022-04-28       Impact factor: 2.847

9.  An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman.

Authors:  Malik Sallam; Rawan Batarseh; Anas Natsheh; Jumana Abbadi; Esraa Al-Fraihat; Alaa' Yaseen; Doaa Kaddomi; Nadia Khamees; Azmi Mahafzah; Gülşen Özkaya Şahin
Journal:  BMC Infect Dis       Date:  2019-12-31       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.